In addition, the mutational burden of EBV-positive DLBCL has been found to be lower than that of EBV-negative DLBCL, and the presence of EBV may substitute for mutations in driver genes, such as MYD88 and CD79A [97]. Here, MYD88 is linked to diffuse large B-cell lymphoma.